BY MICHELLE ERNSTMEYER AND ELIZABETH
CHRISTMANQUESTIONS & 100% VERIFIED ANSWERS AND
RATIONALES | GRADED A+LATEST UPDATE
, TABLE OF CONTENTS W
Q WQ
Textbook chaptersWQ
• Chapter 1: Pharmacokinetics & Pharmacodynamics : Includes basic concepts such a
WQ WQ W Q WQ W
Q W Q W Q WQ WQ WQ
s absorption, distribution, metabolism, and excretion.
WQ W Q W Q W Q WQ
• Chapter 2: Legal/Ethical: Covers safe medication administration, legal guidelines, an
WQ WQ W Q WQ WQ W Q W Q WQ W Q
d preventing medication errors.
WQ W Q W Q
• Chapter 3: Antimicrobials : Focuses on various antimicrobial therapies, includin
WQ WQ W
Q WQ WQ WQ WQ Q
W WQ W Q
g penicillins, cephalosporins, antivirals, and antifungals.
WQ W Q W Q W Q WQ
• Chapter 4: Autonomic Nervous System: Discusses medications related to t
WQ WQ W Q WQ WQ W Q W Q WQ WQ
he autonomic nervous system, including agonists and antagonists.
WQ W Q WQ W Q W Q W Q WQ
• Chapter 5: Respiratory System: Covers medications used for respiratory disorder
WQ WQ WQ WQ WQ W Q WQ WQ W Q
s, such as antihistamines, decongestants, and corticosteroids.
WQ WQ WQ W Q W Q WQ
• Chapter 6: Cardiovascular & Renal Systems: Addresses medications for th
WQ WQ W Q WQ WQ WQ WQ W Q WQ
e cardiovascular and renal systems, including antiarrhythmics, diuretics, an
WQ W Q WQ WQ W Q W Q W Q W Q
d antihypertensives.
WQ
• Chapter 7: Gastrointestinal System: Focuses on medications for the GI system, such a
WQ WQ WQ WQ WQ WQ W Q WQ WQ WQ WQ WQ
s antiulcer medications, laxatives, and antiemetics.
WQ W Q W Q W Q WQ
• Chapter 8: Central Nervous System: Covers CNS depressants, stimulants
WQ WQ W Q WQ WQ WQ WQ W Q
, antidepressants, and anticonvulsants.
WQ W Q WQ
• Chapter 9: Endocrine System: Explores endocrine medications, includin
WQ WQ W Q WQ W Q W Q W Q
g corticosteroids, antidiabetics, and thyroid medications.
WQ W Q W Q WQ W Q
• Chapter 10: Analgesics & Musculoskeletal System: Includes nonopioid and opioi
WQ WQ WQ WQ W
Q WQ W Q W Q WQ
d analgesics, as well as anesthetics.
WQ W Q WQ W Q WQ
,CHAPTER1 — PHARMACOKINETICS & PHARMACODYNAMICS W
Q WQ WQ W
Q WQ
Question 1 WQ
A nurse is teaching a newly licensed nurse about drug absorption. Which factor pri
WQ WQ WQ W Q WQ W Q WQ WQ WQ WQ W
Q WQ WQ
marily affects the rate of absorption after oral administration?
W Q WQ WQ WQ WQ WQ WQ WQ
A. Volume of distribution WQ WQ
B. Gastric emptying time WQ W Q
C. Hepatic enzyme activity WQ WQ
D. Protein binding WQ
Correct answer: B. Gastric emptying time Rationa
W
Q W
Q WQ WQ WQ WQ
le:
• B is correct. Gastric emptying time determines how quickly an orally admi
WQ WQ WQ WQ W Q W Q W Q WQ WQ WQ WQ
nistered drug reaches the small intestine, where most absorption occurs; faste
WQ WQ WQ WQ WQ W Q WQ WQ WQ WQ
r emptying → more rapid absorption.
WQ WQ WQ WQ WQ
• A (Volume of distribution) affects distribution, not initial absorptionrate.
WQ WQ WQ WQ WQ WQ WQ W Q W
Q
• C (Hepatic enzyme activity) influences metabolism (first-
WQ WQ WQ WQ W Q WQ
pass effect) and clearance, not the absorption rate from the GI tract.
WQ WQ WQ W Q WQ WQ WQ WQ WQ WQ WQ
• D (Protein binding) affects free drug available for distribution and action,
WQ WQ WQ WQ WQ WQ W Q WQ WQ WQ WQ
not the physical process/rate of absorption across the GI mucosa.
WQ WQ WQ WQ WQ WQ WQ WQ WQ
Question 2 WQ
A 68-year-
WQ
old patient with decreased renal function is prescribed a drug that is 90% renally e
W Q WQ WQ WQ WQ WQ W Q WQ WQ WQ WQ WQ WQ WQ
xcreted unchanged. Which pharmacokinetic change is most likely and requires nurs
WQ WQ WQ WQ WQ WQ WQ WQ WQ WQ
e action?
WQ
A. Increased hepatic metabolism leading to subtherapeutic levels
WQ WQ WQ W Q WQ WQ
, B. Decreased half-life requiring more frequent dosing WQ W Q WQ WQ WQ
C. Accumulation of the drug causing toxicity WQ WQ WQ WQ WQ
D. Increased first-pass effect reducing bioavailability
WQ WQ WQ WQ
Correct answer: C. Accumulation of the drug causing toxicity Rational
W
Q W
Q WQ WQ WQ WQ WQ WQ WQ
e:
• C is correct. Impaired renal excretion leads to decreased clearance of renal
WQ WQ WQ W Q WQ WQ WQ WQ WQ W Q WQ
ly eliminated drugs and increased accumulation → higher plasma levels and p
WQ W Q WQ WQ WQ WQ WQ WQ WQ WQ WQ
otential toxicity. Nurse should notify prescriber and anticipate dose reductio
WQ WQ WQ WQ WQ WQ WQ WQ WQ
n or extended interval.
WQ WQ WQ
• A (Increasedhepatic metabolism) is unrelated to renal excretion.
WQ W
Q WQ WQ WQ W Q WQ WQ
• B (Decreasedhalf-life) is oppositeof expected; renal impairment typically
WQ W
Q WQ WQ W
Q WQ WQ WQ W Q
increases half-life. WQ
• D (Increasedfirst-
WQ W
Q
pass effect) refers to hepatic metabolism and would decrease bioavailab
WQ WQ WQ WQ W Q WQ WQ WQ WQ
ility; not the primary issue with renal impairment.
W Q WQ WQ WQ WQ WQ WQ
Question 3 WQ
Which statement bestdescribes volume of distribution (Vd)?
WQ WQ W
Q WQ WQ WQ WQ
A. Vd indicates how rapidly a drug is absorbed from the GI tract.
WQ WQ WQ W Q WQ WQ WQ WQ W
Q WQ WQ
B. A high Vd suggests extensive distribution into tissues.
WQ WQ WQ WQ WQ WQ WQ
C. Vd is a direct measure of plasma protein binding.
WQ WQ WQ WQ WQ WQ WQ WQ
D. Vd equals the percentage of drug eliminated by the kidneys.
WQ WQ WQ WQ WQ WQ W Q WQ WQ
Correct answer: B. A high Vd suggests extensive distribution into tissues. Rat
W
Q W
Q WQ WQ WQ WQ WQ WQ WQ WQ WQ
ionale: